Trial Profile

Phase II Clinical Trial of Safety, Pharmacokinetics and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Adult Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2024 Primary endpoint has been met. (Percentage change from baseline in EASI 300mg Q4W), as per Results presented at the American Academy of Dermatology annual Meeting 2024
12 Mar 2024 Primary endpoint has been met. (Percentage change from baseline in EASI 300mg Q2W), as per results presented at the American Academy of Dermatology annual Meeting 2024
12 Mar 2024 Primary endpoint has not been met. (Percentage change from baseline in EASI 150mg Q4W), as per results presented at the American Academy of Dermatology annual Meeting 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com